Existing evidence is not sufficient to strongly advocate the usage of IVM and DOXY, either as monotherapy or as a combination therapy, in the treatment of COVID-19. However, it should be considered that both of these drugs have several advantages associated with them, such as viable mechanism of action, easy availability, acceptable safety profile, experience of long-term use and inexpensiveness. Because a lack of evidence for efficacy does not necessarily mean evidence for lack of efficacy, and also because the prophylactic role of IVM has been recently reported in the literature, further studies are essential to explore if this combination has the potential to manage patients with COVID-19, and to find out if this combination is a solution for the long-sought drug of choice for COVID-19 management.
...
We did not assess the role of IVM or DOXY in COVID-19 prophylaxis.
[-] TehCaster | 5 points | Apr 18 2021 00:36:37
Conclusions
Existing evidence is not sufficient to strongly advocate the usage of IVM and DOXY, either as monotherapy or as a combination therapy, in the treatment of COVID-19. However, it should be considered that both of these drugs have several advantages associated with them, such as viable mechanism of action, easy availability, acceptable safety profile, experience of long-term use and inexpensiveness. Because a lack of evidence for efficacy does not necessarily mean evidence for lack of efficacy, and also because the prophylactic role of IVM has been recently reported in the literature, further studies are essential to explore if this combination has the potential to manage patients with COVID-19, and to find out if this combination is a solution for the long-sought drug of choice for COVID-19 management.
...
We did not assess the role of IVM or DOXY in COVID-19 prophylaxis.
permalink